| Pacific Biomarkers Awarded Major Research Contract as Part of Phase I Cardiovascular Program (PR Newswire) Pacific Biomarkers, Inc. has been awarded a contract by a leading multinational pharmaceutical company to provide essential laboratory data for an adaptive Phase I cardiovascular trial. us.rd.yahoo.com |
Highlights of the RESILIENT Trial - Video TRIAL DATA DEMONSTRATES BARD LifeStent® VASCULAR STENT IS SUPERIOR TO ANGIOPLASTY FOR LESIONS IN SUPERFICIAL FEMORAL ARTERY AND PROXIMAL POPLITEAL ARTERY feedproxy.google.com |
Did the Market Overreact to Curis's Latest Setback? EP Vantage submits:Curis (CRIS) was punished on the stock market for the second time in as many months Monday after releasing a disappointingly opaque announcement on a phase II trial of its lead candidate, the hedgehog pathway inhibitor GDC-0449, in ovarian cancer. In what could politely be described as a vague statement, Curis said further analyses are needed before a decision on continuing development can be taken. This has prompted investors to conclude that study has, or will, fail and comes at an unsteady time for Curis, following so soon after the drug’s failure in colon cancer (CRC) in June (Prickly response as Curis' hedgehog candidate disappoints, June 17, 2010). However, it is worth bearing in mind that Roche (RHHBY.PK) is pitting this first-in-class candidate in numerous tumor types, and phase II data from the most promising setting, basal cell carcinoma (BCC), has yet to be seen. The drug’s potential might seem to be narrowing, and it certainly remains high risk, but it is too early to completely write it off, something that the stock market appears to be doing.Complete Story » seekingalpha.com |
J&J Seeks Remicade Damages Johnson & Johnson is seeking damages from Merck as it negotiates to dissolve a partnership over the big-selling rheumatoid arthritis drug Remicade. online.wsj.com |
Glaxo to Pay $750 Million in Pact Glaxo agreed to pay $750 million and plead guilty to a criminal charge to settle a U.S. government investigation of manufacturing deficiencies at its former plant in Puerto Rico. online.wsj.com |